NANJING, China, Nov. 10, 2025 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells (Treg) -preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study in China for the treatment of...
Hence then, the article about simcere s il 2 mutant fusion protein sim0278 entered phase ii clinical trial stage was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage )
Also on site :
- ‘Change is inevitable’: What is next for Iran?
- Travel Warning Issued For Millions Across US
- Australian Open: Sinner overcomes cramps; Keys, Pegula advance; Osaka withdraws